BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 吸入性糖皮质激素（ICS）单药治疗轻中度持续性哮喘儿童已被证明是有益的，在大多数儿童。 研究哮喘治疗方案的自然下一步是确定最佳的附加药物（增加ICS，LABA或LTRA），当ICS单药治疗不足以令人满意地控制哮喘时。 BADGER或最佳辅助治疗给予有效反应，将回答180名儿童（每个临床中心36名）的最佳辅助药物问题，这些儿童有轻度至中度哮喘史，并且在低剂量ICS治疗下未完全控制。 研究设计是三重交叉，每个儿童接受每种添加药物。 主要结局将是基于哮喘急性发作的治疗反应、哮喘控制天数和一秒用力呼气量的变化（肺功能测试）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monotherapy with inhaled corticosteroid (ICS) in mild to moderate persistent asthma in children has been shown to be beneficial in most children. The natural next step in studying asthma therapy options is determining the optimal add-on medication (increasing ICS, LABA or LTRA) to ICS when monotherapy with ICS at that dose is inadequate to control asthma satisfactorily. BADGER, or Best Add-on Therapy Giving Effective Responses, will answer the question about best add-on medication in 180 children (36 per clinical center) who have a history of mild to moderate asthma and are not completely controlled on low dose ICS. The study design is a triple cross over with each child receiving each add-on medication. The primary outcomes will be treatment response based on asthma exacerbation, asthma control days, and change in forced expiratory volume in one second (lung function testing).